<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185302</url>
  </required_header>
  <id_info>
    <org_study_id>91410</org_study_id>
    <secondary_id>2004-002395-41</secondary_id>
    <secondary_id>309100</secondary_id>
    <nct_id>NCT00185302</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma</brief_title>
  <official_title>Phase II Study of MS-275, a Histone Deacetylase Inhibitor, Comparing 2 Dosage Schedules in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To evaluate the efficacy of two different dosing schedules of MS-275 in&#xD;
      subjects with metastatic melanoma Secondary objectives: To evaluate the safety and to assess&#xD;
      the pharmacokinetic profile of MS-275 in subjects with metastatic melanoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been&#xD;
      renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor&#xD;
      of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall tumor response rate (the proportion of subjects with the best tumor response of PR or CR within the first 6 cycles of treatment)</measure>
    <time_frame>Baseline, 8, 16, 24, 32 weeks (cycle 6)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
    <time_frame>Baseline, every 8 weeks until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate at each tumor assessment time point (CR/PR/SD/PD/not assessable)</measure>
    <time_frame>At baseline and repeated every 2 cycles until tumor progression between Day 22 of even numbered cycles and Day 1 of subsequent odd numbered cycle and also at EOT and F-up visiit (90 days after the EOT and every 3 months until disease progression)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Baseline, every 8 weeks until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Approximately 8-64 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Histone Deacetylase Inhibitor, 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Histone Deacetylase Inhibitor, 7 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)</intervention_name>
    <description>MS-275, 3 mg on Days 1 and 15 of a 4-week cycle</description>
    <arm_group_label>Histone Deacetylase Inhibitor, 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)</intervention_name>
    <description>MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle</description>
    <arm_group_label>Histone Deacetylase Inhibitor, 7 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects with Stage III or IV non-resectable nonuveal (cutaneous or mucosal)&#xD;
             metastatic melanoma who had received at least one but no more than two previous&#xD;
             systemic therapies (immunotherapy and/or chemotherapy) for metastatic disease and who&#xD;
             had not responded to or who had progressed after their most recent therapy were&#xD;
             eligible for enrollment&#xD;
&#xD;
          -  Presence of at least one lesion fulfilling the minimum Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST) size requirements for a target lesion - Use of highly effective&#xD;
             birth control methods in females of child-bearing potential&#xD;
&#xD;
          -  Able to undergo either contrast enhanced computed tomography (CT) scan or contrast&#xD;
             enhanced magnetic resonance imaging (MRI) scan for tumor assessment&#xD;
&#xD;
          -  Life expectancy greater than 3 months&#xD;
&#xD;
          -  Adequate organ and bone marrow functions as defined below: absolute neutrophil count ≥&#xD;
             1500 /µL, platelets ≥ 100,000 /µL, creatinine ≤ 1.5 × upper limit of normal (ULN) or&#xD;
             measured creatinine clearance of ≥ 60 mL/min x 1.73 m2 body surface area, total&#xD;
             bilirubin ≤ 1.5 times ULN, aspartate aminotransferase or serum glutamic oxalacetic&#xD;
             transaminase/alanine aminotransferase or serum glutamic pyruvic transaminase∗ ≤ 2.5&#xD;
             times ULN&#xD;
&#xD;
          -  Negative serum pregnancy test within 2 weeks prior to receiving the first dose of&#xD;
             study drug in female subjects of childbearing potential. Agreement to use a highly&#xD;
             effective method of birth control throughout the study period and 3 months thereafter&#xD;
             for sexually active males and females of childbearing potentia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active malignancy in the last five years&#xD;
&#xD;
          -  Pregnancy, breast feeding&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Brain metastasis&#xD;
&#xD;
          -  Concomitant use of corticosteroids or valproic acid&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Diagnosis of uveal melanoma&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status ≥ 2&#xD;
&#xD;
          -  Ongoing effects from previous investigational drug studies or concomitant&#xD;
             participation in other investigational drug studies&#xD;
&#xD;
          -  Prior use of MS-275 or any other HDAC inhibitor&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to MS-275&#xD;
&#xD;
          -  Anticancer therapy&#xD;
&#xD;
          -  Active gastrointestinal conditions that might predispose for poor drug absorption&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to enrollment&#xD;
&#xD;
          -  Hypophosphatemia &lt; 2.5 mg/dL at screening, if not corrected in the screening period&#xD;
&#xD;
          -  Medical, psychiatric or other conditions that compromise the patient's ability to&#xD;
             understand the patient information, to give informed consent, to comply with the trial&#xD;
             protocol, or to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-resectable metastatic melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entinostat</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

